BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

236 related articles for article (PubMed ID: 20150307)

  • 21. Evaluation of early response to SU101 target-based therapy in patients with recurrent supratentorial malignant gliomas using FDG PET and Gd-DTPA MRI.
    Vlassenko AG; Thiessen B; Beattie BJ; Malkin MG; Blasberg RG
    J Neurooncol; 2000; 46(3):249-59. PubMed ID: 10902856
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Diffusion-weighted MRI and ADC versus FET-PET and GdT1w-MRI for gross tumor volume (GTV) delineation in re-irradiation of recurrent glioblastoma.
    Popp I; Bott S; Mix M; Oehlke O; Schimek-Jasch T; Nieder C; Nestle U; Bock M; Yuh WTC; Meyer PT; Weber WA; Urbach H; Mader I; Grosu AL
    Radiother Oncol; 2019 Jan; 130():121-131. PubMed ID: 30219612
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Diagnostic performance of 18F-fluorodeoxyglucose positron emission tomography in the evaluation of glioma.
    Shaw TB; Jeffree RL; Thomas P; Goodman S; Debowski M; Lwin Z; Chua B
    J Med Imaging Radiat Oncol; 2019 Oct; 63(5):650-656. PubMed ID: 31368665
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Potential influence of Gadolinium contrast on image segmentation in MR-based attenuation correction with Dixon sequences in whole-body 18F-FDG PET/MR.
    Ruhlmann V; Heusch P; Kühl H; Beiderwellen K; Antoch G; Forsting M; Bockisch A; Buchbender C; Quick HH
    MAGMA; 2016 Apr; 29(2):301-8. PubMed ID: 26667965
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Differentiation between Treatment-Induced Necrosis and Recurrent Tumors in Patients with Metastatic Brain Tumors: Comparison among
    Tomura N; Kokubun M; Saginoya T; Mizuno Y; Kikuchi Y
    AJNR Am J Neuroradiol; 2017 Aug; 38(8):1520-1527. PubMed ID: 28619837
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Glial tumor grading and outcome prediction using dynamic spin-echo MR susceptibility mapping compared with conventional contrast-enhanced MR: confounding effect of elevated rCBV of oligodendrogliomas [corrected].
    Lev MH; Ozsunar Y; Henson JW; Rasheed AA; Barest GD; Harsh GR; Fitzek MM; Chiocca EA; Rabinov JD; Csavoy AN; Rosen BR; Hochberg FH; Schaefer PW; Gonzalez RG
    AJNR Am J Neuroradiol; 2004 Feb; 25(2):214-21. PubMed ID: 14970020
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Correlation between apparent diffusion coefficients on diffusion-weighted MRI and standardized uptake value on FDG-PET/CT in pancreatic adenocarcinoma.
    Sakane M; Tatsumi M; Kim T; Hori M; Onishi H; Nakamoto A; Eguchi H; Nagano H; Wakasa K; Hatazawa J; Tomiyama N
    Acta Radiol; 2015 Sep; 56(9):1034-41. PubMed ID: 25267921
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Correlation of the apparent diffusion coefficient (ADC) and standardized uptake values (SUV) with overall survival in patients with primary non-small cell lung cancer (NSCLC) using
    Bruckmann NM; Kirchner J; Grueneisen J; Li Y; McCutcheon A; Aigner C; Rischpler C; Sawicki LM; Herrmann K; Umutlu L; Schaarschmidt BM
    Eur J Radiol; 2021 Jan; 134():109422. PubMed ID: 33271432
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Applying Amide Proton Transfer MR Imaging to Hybrid Brain PET/MR: Concordance with Gadolinium Enhancement and Added Value to [
    Sun H; Xin J; Zhou J; Lu Z; Guo Q
    Mol Imaging Biol; 2018 Jun; 20(3):473-481. PubMed ID: 29063304
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Progressing Toward a Cohesive Pediatric 18F-FDG PET/MR Protocol: Is Administration of Gadolinium Chelates Necessary?
    Klenk C; Gawande R; Tran VT; Leung JT; Chi K; Owen D; Luna-Fineman S; Sakamoto KM; McMillan A; Quon A; Daldrup-Link HE
    J Nucl Med; 2016 Jan; 57(1):70-7. PubMed ID: 26471690
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A Population-Based Gaussian Mixture Model Incorporating 18F-FDG PET and Diffusion-Weighted MRI Quantifies Tumor Tissue Classes.
    Divine MR; Katiyar P; Kohlhofer U; Quintanilla-Martinez L; Pichler BJ; Disselhorst JA
    J Nucl Med; 2016 Mar; 57(3):473-9. PubMed ID: 26659350
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Grading of brain glioma with 1-11C-acetate PET: comparison with 18F-FDG PET.
    Tsuchida T; Takeuchi H; Okazawa H; Tsujikawa T; Fujibayashi Y
    Nucl Med Biol; 2008 Feb; 35(2):171-6. PubMed ID: 18312826
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Multimodal imaging-defined subregions in newly diagnosed glioblastoma: impact on overall survival.
    John F; Bosnyák E; Robinette NL; Amit-Yousif AJ; Barger GR; Shah KD; Michelhaugh SK; Klinger NV; Mittal S; Juhász C
    Neuro Oncol; 2019 Feb; 21(2):264-273. PubMed ID: 30346623
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Discrimination between low-grade oligodendrogliomas and diffuse astrocytoma with the aid of 11C-methionine positron emission tomography.
    Shinozaki N; Uchino Y; Yoshikawa K; Matsutani T; Hasegawa A; Saeki N; Iwadate Y
    J Neurosurg; 2011 Jun; 114(6):1640-7. PubMed ID: 21214332
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Correlation of apparent diffusion coefficients measured by 3T diffusion-weighted MRI and SUV from FDG PET/CT in primary cervical cancer.
    Ho KC; Lin G; Wang JJ; Lai CH; Chang CJ; Yen TC
    Eur J Nucl Med Mol Imaging; 2009 Feb; 36(2):200-8. PubMed ID: 18779960
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Ferumoxytol Does Not Impact Standardized Uptake Values on PET/MR Scans.
    Muehe AM; Yerneni K; Theruvath AJ; Thakor AS; Pribnow A; Avedian R; Steffner R; Rosenberg J; Hawk KE; Daldrup-Link HE
    Mol Imaging Biol; 2020 Jun; 22(3):722-729. PubMed ID: 31325083
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Comparison between MRI-derived ADC maps and
    Berro DH; Collet S; Constans JM; Barré L; Derlon JM; Emery E; Guillamo JS; Valable S
    J Neuroradiol; 2019 Nov; 46(6):359-366. PubMed ID: 31229576
    [TBL] [Abstract][Full Text] [Related]  

  • 38. 18F-FDG PET/MR imaging of lymphoma nodal target lesions: Comparison of PET standardized uptake value (SUV) with MR apparent diffusion coefficient (ADC).
    Bernstine H; Domachevsky L; Nidam M; Goldberg N; Abadi-Korek I; Shpilberg O; Groshar D
    Medicine (Baltimore); 2018 Apr; 97(16):e0490. PubMed ID: 29668631
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Correlation of biological aggressiveness assessed by 11C-methionine PET and hypoxic burden assessed by 18F-fluoromisonidazole PET in newly diagnosed glioblastoma.
    Kawai N; Maeda Y; Kudomi N; Miyake K; Okada M; Yamamoto Y; Nishiyama Y; Tamiya T
    Eur J Nucl Med Mol Imaging; 2011 Mar; 38(3):441-50. PubMed ID: 21072512
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Hypoxic glucose metabolism in glioblastoma as a potential prognostic factor.
    Toyonaga T; Yamaguchi S; Hirata K; Kobayashi K; Manabe O; Watanabe S; Terasaka S; Kobayashi H; Hattori N; Shiga T; Kuge Y; Tanaka S; Ito YM; Tamaki N
    Eur J Nucl Med Mol Imaging; 2017 Apr; 44(4):611-619. PubMed ID: 27752745
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.